Andrew Imbus, PA
Medical · Arcadia, CANPI 1073645263
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 67.5% of it on its own, with 15 other manufacturers making up the rest. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $60.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$23K
- Boston Scientific$5K
- Amneal Pharmaceuticals LLC$2K
- AbbVie$970
- Medtronic$674
- Neurocrine Biosciences, Inc.$628
- plus $1K from 10 others
What the payments were for
- Consulting fees$4,76514%
- Speaking & faculty fees$8,86427%
- Travel & lodging$5,86118%
- Food & beverage$13,90142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 244 | $22,551 |
| Boston Scientific | 238 | $5,132 |
| Amneal Pharmaceuticals LLC | 9 | $2,378 |
| AbbVie | 23 | $970 |
| Medtronic | 18 | $674 |
| Neurocrine Biosciences, Inc. | 5 | $628 |
| Teva Pharmaceuticals USA, Inc. | 4 | $274 |
| Merz Pharmaceuticals, LLC | 3 | $263 |
| MDD US Operations, LLC | 1 | $144 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Ipsen Biopharmaceuticals, Inc | 3 | $85 |
| Supernus Pharmaceuticals, Inc. | 1 | $63 |
| Acadia Pharmaceuticals Inc | 1 | $33 |
| SK Life Science, Inc. | 1 | $30 |
| GE HealthCare | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$15,323
- Infinity DBS Pulse Generators$1,510
- RYTARY$1,352
- IonicRF Generator$715
- INGREZZA$628
- GENERAL DBS$394
- XEOMIN$245
- Austedo XR$245
- TheraSphere Administration Set$151
- SYNCHROMED$145
- GOCOVRI$144
- VYALEV$125
- ZENPEP$125
- Duopa$113
How this compares
$33,391 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 87 | $473,597 |
| RytaryCarbidopa/Levodopa | 55 | $141,307 |
| InbrijaLevodopa | 29 | $120,020 |
| Austedo XrDeutetrabenazine | 11 | $55,465 |
| GocovriAmantadine Hcl | 25 | $48,441 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 488 | $36,234 |
| NeuproRotigotine | 19 | $20,995 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $20,728 |
| BotoxOnabotulinumtoxina | 15 | $18,069 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 116 | $9,668 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 26 | $9,612 |
| Entacapone | 57 | $7,423 |
| Selegiline Hcl | 32 | $6,115 |
| Tetrabenazine | 14 | $5,975 |
| Carbidopa | 18 | $5,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $33 | $473,59787 claims |
| Amneal Pharmaceuticals LLCRytary | $2,378 | $141,30755 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $274 | $55,46511 claims |
| MDD US Operations, LLCGocovri | $144 | $48,44125 claims |
| AbbVieBotox | $970 | $18,06915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Arcadia
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
- Cheryl KyinnSan Diego$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.